FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362541570> ?p ?o ?g. }

• W4362541570 endingPage "5746" @default.
• W4362541570 startingPage "5746" @default.
• W4362541570 abstract "Abstract Efficacy of Chimeric Antigen Receptor (CAR) T cell therapy against solid tumors is hampered by multiple barriers, including tumor-associated immunosuppression, poor CAR-T cell trafficking into solid tumor masses and shortage of highly expressed cancer-specific target antigens. The T-SIGn (Tumor Specific ImmunoGene) platform generates viral vectors that can produce combinations of transgenes selectively within the tumor microenvironment (TME). T-SIGn is clinically validated for intravenous (i.v.) delivery, enabling vectors to reach primary and metastatic sites to produce their therapeutic payloads specifically in malignant epithelial cells. Using an A549 human tumor xenograft and metastasis model, we previously demonstrated that i.v. administration of a T-SIGn vector encoding IFNα, MIP1α and CD80 results into potentiated CAR-T cell activation and therapy efficacy (Sonzogni et al. 2022). Here, we further evaluated the potential of T-SIGn combination with Cell Therapy by investigating the impact on CAR-T cell activity of vectors encoding different arrays of cytokines and chemokines. Using an in vivo A549 model and anti-HER2 CAR-T cells in NSG mice, we demonstrated that T-SIGn vectors can enable effective CAR-T cell therapy against solid tumors by providing diverse localized cytokine/chemokine-mediated T cell boosting, with IL-12-encoding vectors resulting in complete and durable tumor clearance. Furthermore, we explored the use of the T-SIGn platform to encode secreted bispecific “adaptor” molecules able to simultaneously bind to a tumor surface antigen and to a CAR specific for an antigen not naturally expressed by the tumor, allowing the redirection of CAR-T cells against desired tumor types. We designed a vector (NG-1125) encoding an anti-HER2 ScFv_CD19 bispecific construct as a model “adaptor” molecule, together with IFNα and CXCL9, and we showed that this construct can effectively redirect anti-CD19 CAR-T cell against HER2+CD19− tumor cells. In vitro X-CELLigence-based cytotoxicity assays demonstrated killing of both HER2+CD19− A549 and SKOV3 cells by anti-CD19 CAR-T cells in presence of vector-derived anti-HER2 ScFv_CD19. Following i.v. NG-1125 dosing of A549 tumor-bearing mice, ex vivo flow cytometry analysis of tumor masses revealed binding of the encoded adaptor molecule to both vector-infected and uninfected tumor cells. Furthermore, in vivo NG-1125 administration together with anti-CD19 CAR-T cells resulted into increased intra-tumoral densities of transferred T cells. Collectively, these data show the potential of T-SIGn vectors in overcoming solid tumor resistance mechanisms to CAR-T and pave the way for the development of other immunotherapeutics to be expressed within the TME via T-SIGn vectors in combination with CAR or TCR-based therapies. Citation Format: Maria Stella Sasso, Rachel Bergin, Rochelle Lear, Darren Plumb, Manuela Zonca, Eva Vainiute, Meg Snowden, Tae Hyun Jang, Alice Muntzer, Carla C. Cerqueira, Katy West, Samantha Bucktrout, Brian R. Champion. Flexible tumor-specific cytokine and antigen delivery through the T-SIGn vector platform enables effective CAR-T cell therapy against solid tumors. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5746." @default.
• W4362541570 created "2023-04-06" @default.
• W4362541570 creator A5031204927 @default.
• W4362541570 creator A5035634634 @default.
• W4362541570 creator A5039210456 @default.
• W4362541570 creator A5043264134 @default.
• W4362541570 creator A5048166087 @default.
• W4362541570 creator A5048180481 @default.
• W4362541570 creator A5051769499 @default.
• W4362541570 creator A5060691243 @default.
• W4362541570 creator A5062805048 @default.
• W4362541570 creator A5081794708 @default.
• W4362541570 creator A5083243619 @default.
• W4362541570 creator A5083859070 @default.
• W4362541570 creator A5091753055 @default.
• W4362541570 date "2023-04-04" @default.
• W4362541570 modified "2023-10-16" @default.
• W4362541570 title "Abstract 5746: Flexible tumor-specific cytokine and antigen delivery through the T-SIGn vector platform enables effective CAR-T cell therapy against solid tumors" @default.
• W4362541570 doi "https://doi.org/10.1158/1538-7445.am2023-5746" @default.
• W4362541570 hasPublicationYear "2023" @default.
• W4362541570 type Work @default.
• W4362541570 citedByCount "0" @default.
• W4362541570 crossrefType "journal-article" @default.
• W4362541570 hasAuthorship W4362541570A5031204927 @default.
• W4362541570 hasAuthorship W4362541570A5035634634 @default.
• W4362541570 hasAuthorship W4362541570A5039210456 @default.
• W4362541570 hasAuthorship W4362541570A5043264134 @default.
• W4362541570 hasAuthorship W4362541570A5048166087 @default.
• W4362541570 hasAuthorship W4362541570A5048180481 @default.
• W4362541570 hasAuthorship W4362541570A5051769499 @default.
• W4362541570 hasAuthorship W4362541570A5060691243 @default.
• W4362541570 hasAuthorship W4362541570A5062805048 @default.
• W4362541570 hasAuthorship W4362541570A5081794708 @default.
• W4362541570 hasAuthorship W4362541570A5083243619 @default.
• W4362541570 hasAuthorship W4362541570A5083859070 @default.
• W4362541570 hasAuthorship W4362541570A5091753055 @default.
• W4362541570 hasConcept C147483822 @default.
• W4362541570 hasConcept C203014093 @default.
• W4362541570 hasConcept C2776090121 @default.
• W4362541570 hasConcept C2776107976 @default.
• W4362541570 hasConcept C2776662205 @default.
• W4362541570 hasConcept C2777701055 @default.
• W4362541570 hasConcept C3020616263 @default.
• W4362541570 hasConcept C3875195 @default.
• W4362541570 hasConcept C502942594 @default.
• W4362541570 hasConcept C71924100 @default.
• W4362541570 hasConcept C8891405 @default.
• W4362541570 hasConceptScore W4362541570C147483822 @default.
• W4362541570 hasConceptScore W4362541570C203014093 @default.
• W4362541570 hasConceptScore W4362541570C2776090121 @default.
• W4362541570 hasConceptScore W4362541570C2776107976 @default.
• W4362541570 hasConceptScore W4362541570C2776662205 @default.
• W4362541570 hasConceptScore W4362541570C2777701055 @default.
• W4362541570 hasConceptScore W4362541570C3020616263 @default.
• W4362541570 hasConceptScore W4362541570C3875195 @default.
• W4362541570 hasConceptScore W4362541570C502942594 @default.
• W4362541570 hasConceptScore W4362541570C71924100 @default.
• W4362541570 hasConceptScore W4362541570C8891405 @default.
• W4362541570 hasIssue "7_Supplement" @default.
• W4362541570 hasLocation W43625415701 @default.
• W4362541570 hasOpenAccess W4362541570 @default.
• W4362541570 hasPrimaryLocation W43625415701 @default.
• W4362541570 hasRelatedWork W1974496092 @default.
• W4362541570 hasRelatedWork W2499376085 @default.
• W4362541570 hasRelatedWork W2592882744 @default.
• W4362541570 hasRelatedWork W3024178724 @default.
• W4362541570 hasRelatedWork W3046189784 @default.
• W4362541570 hasRelatedWork W4293222486 @default.
• W4362541570 hasRelatedWork W4308377693 @default.
• W4362541570 hasRelatedWork W4310980338 @default.
• W4362541570 hasRelatedWork W4320922744 @default.
• W4362541570 hasRelatedWork W4381377675 @default.
• W4362541570 hasVolume "83" @default.
• W4362541570 isParatext "false" @default.
• W4362541570 isRetracted "false" @default.
• W4362541570 workType "article" @default.